AstraZeneca, Johnson & Johnson and rare thrombosis: cases in Europe

Vaccines AstraZeneca and Johnson & Johnson, how many cases of rare thrombosis in Europe? “To date we have 10 possible cases of thrombosis associated with thrombocytopenia in over 6 million people vaccinated against Covid with the J&J vaccine in the European Economic Area”. And “out of 45 million vaccinated with AstraZeneca we have 405 potential cases” of these atypical thrombosis with low platelet levels. This is the figure reported by Georgy Genov, head of Pharmacoviliness of the European Medicines Agency Ema, today during the periodic briefing held by the EU regulatory body. “We will carefully review these possible cases which remain rare,” he added. Read also “The Prac Pharmacovigilance Committee of the European Medicines Agency EMA is currently continuing to analyze the reports of myocarditis and pericarditis reported after vaccination against Covid with mRna products. We have been closely monitoring this aspect since April, but there are not enough data to establish a causal link at this time “, said Noël Wathion, Deputy Executive Director of the European Medicines Agency Ema.” However, it seems that the number of cases is very low “and that these myocarditis and pericarditis occur in” moderate form and resolve within a few days. Some patients have been hospitalized, but have recovered – explained the expert – We encourage healthcare professionals to report these cases and other potential adverse effects and people to seek medical attention in case of symptoms. We will continue to monitor these conditions and consider further action if necessary. “